Photo: in.investing.com
Lonza Seals Major Supply Deal at U.S. Biologics Hub, Boosting Stock Prices
Lonza Groups stock surged after announcing a significant long-term supply deal at its Vacaville, California biologics manufacturing site, highlighting robust customer demand.
- Lonza Group confirmed a long-term commercial supply agreement at its manufacturing site in Vacaville, California, boosting stock prices during early European trading on Thursday.
- The Vacaville, California facility, acquired from Roche in 2024 for $1.2 billion, has seen sustained high customer interest, according to Lonza Groups statement.
- This deal marks a strategic move for Lonza Group as it capitalizes on increasing demand for biologic drugs at one of the worlds largest manufacturing sites.
Por Qué Es Relevante
This significant agreement positions Lonza Group at the forefront of the growing biologics market, reflecting increasing investor confidence and the companys strategic expansion in the U.S. pharmaceutical landscape.